Anti-EGFR antibodies may get benefit as first-line treatment in metastatic right-sided colon cancer

被引：0
|
作者：
Elbaiomy, M. [1 ]
Elsayed, A. [2 ]
Akl, T. [1 ]
机构：
[1] Mansoura Univ, Oncol Ctr, Mansoura, Egypt
[2] Fac Med, Mansoura, Egypt
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.272
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-182
引用
收藏
页码：S314 / S315
页数：2
相关论文
共 50 条
  • [1] No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
    Sunakawa, Y.
    Tsuji, A.
    Fujii, M.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 2030 - 2031
  • [2] Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong?
    Weinberg, Benjamin A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12): : 1547 - 1548
  • [3] Bevacizumab in the first-line treatment of metastatic right-sided colon cancer: Does it influence patients' outcome?
    Ingrid, Garajova
    Veronica, Mollica
    Maria, Massucci
    Francesca, Abbati
    Andrea, Palloni
    Giorgio, Frega
    Ilaria, Maggio
    Giovanni, Brandi
    Guido, Biasco
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer
    Boisteau, Emeric
    Lespagnol, Alexandra
    De Tayrac, Marie
    Corre, Sebastien
    Perrot, Anthony
    Rioux-Leclercq, Nathalie
    Martin-Lanneree, Severine
    Artru, Pascal
    Chalabreysse, Philippe
    Poureau, Pierre-Guillaume
    Doucet, Laurent
    Coupez, Dahna
    Bennouna, Jaafar
    Bossard, Celine
    Coriat, Romain
    Beuvon, Frederic
    Bauguion, Lucile
    Leclair, Francois
    Chautard, Romain
    Lecomte, Thierry
    Guyetant, Serge
    Desgrippes, Romain
    Grasset, Denis
    Lhostis, Helene
    Bouhier-Leporrier, Karine
    Bibeau, Frederic
    Edeline, Julien
    Galibert, Marie-Dominique
    Lievre, Astrid
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (05)
  • [5] Focus on metastatic right-sided colon cancer: the best overall response to the first-line non-EGFR treatment correlates with better overall survival
    Abbati, F.
    Massucci, M.
    Mollica, V.
    Palloni, A.
    Barbera, M. A.
    Frega, G.
    Ferracin, M.
    Porcellini, E.
    Brandi, G.
    Biasco, G.
    Garajova, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] The best overall response to the first-line but not to the second-line treatment correlates with outcome of metastatic right-sided and left-sided colon cancer
    Ingrid, Garajova
    Giorgio, Frega
    Andrea, Palloni
    Francesca, Abbati
    Maria, Massucci
    Veronica, Mollica
    Giovanni, Brandi
    Guido, Biasco
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial
    Vitali, Francesco
    Merkel, Susanne
    Schubart, Christoph
    Schmid, Axel
    Eckstein, Markus
    Stoehr, Robert
    Kersting, Stephan
    Hartmann, Arndt
    Gruetzmann, Robert
    Wein, Axel
    ANTI-CANCER DRUGS, 2024, 35 (09) : 844 - 851
  • [8] Anti-EGFR therapy in first-line colorectal cancer
    Lamas, Maria J.
    Duran, Goretti
    Gallardo, Elena
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1499 - 1503
  • [9] Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials
    You, Xia-Hong
    Jiang, Yu-Huan
    Fang, Zhou
    Sun, Fan
    Li, Yao
    Wang, Wei
    Xia, Zi-Jin
    Wang, Xiao-Zhong
    Ying, Hou-Qun
    ESMO OPEN, 2020, 5 (02)
  • [10] Comparison of the effects of anti-EGFR and anti-VEGF antibody as first-line treatment for metastatic colorectal cancer
    Kawamoto, Yasuyuki
    Inoue, Masaki
    Shimizu, Sachiko
    Matsumoto, Mio
    Haba, Shin
    Yokoyama, Akiko
    Yoshii, Shinji
    Akakura, Nobuaki
    ANNALS OF ONCOLOGY, 2015, 26 : 130 - 130
12345